XBiotech Inc. (XBIT) News
Filter XBIT News Items
XBIT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XBIT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest XBIT News From Around the Web
Below are the latest news stories about XBIOTECH INC that investors may wish to consider to help them evaluate XBIT as an investment opportunity.
XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%Key Insights Significant control over XBiotech by individual investors implies that the general public has more power... |
XBiotech Pauses Rheumatology programFindings from recently completed Rheumatoid Arthritis Study raise questionsAUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid Arthritis. The Phase II study failed to meet its primary endpoint amid substantial irregularities that make unequivocal |
XBiotech: Q2 Earnings SnapshotAUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Monday reported a loss of $13 million in its second quarter. The Austin, Texas-based company said it had a loss of 43 cents per share. |
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerFindings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen |
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insidersKey Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by... |